Cabaletta Bio Inc Total Liabilities
Cabaletta Bio Inc total liabilities. Based on the latest financial reports, Cabaletta Bio Inc (CABA) has total liabilities worth $46.13 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Cabaletta Bio Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cabaletta Bio Inc (2017–2025)
Total liabilities of Cabaletta Bio Inc from 2017 to 2025. This chart illustrates how Cabaletta Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CABA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cabaletta Bio Inc Competitors by Total Liabilities
The table below lists competitors of Cabaletta Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Q32 Bio Inc
NASDAQ:QTTB
|
USA | $9.96 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$718.61K |
|
Eaton Vance National Municipal Opportunities Closed Fund
NYSE:EOT
|
USA | $42.58 Million |
|
Suprema Inc
KQ:236200
|
Korea | ₩28.79 Billion |
|
P.C.B Tec
TA:PCBT
|
Israel | ILA76.95 Million |
|
Joyvio Agriculture Development Co Ltd
SHE:300268
|
China | CN¥1.36 Billion |
|
AbClon Inc
KQ:174900
|
Korea | ₩11.43 Billion |
|
Vimta Labs Limited
NSE:VIMTALABS
|
India | Rs-4.57 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Cabaletta Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cabaletta Bio Inc balance sheet assets.
Liquidity & Leverage Metrics
Cabaletta Bio Inc Total Liabilities Ratios Explained
Cabaletta Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cabaletta Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cabaletta Bio Inc (2017–2025)
The table below shows the annual total liabilities of Cabaletta Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.03 Million | +62.12% |
| 2024-12-31 | $32.71 Million | +87.43% |
| 2023-12-31 | $17.45 Million | +40.20% |
| 2022-12-31 | $12.45 Million | +48.54% |
| 2021-12-31 | $8.38 Million | +61.78% |
| 2020-12-31 | $5.18 Million | +64.60% |
| 2019-12-31 | $3.15 Million | -92.99% |
| 2018-12-31 | $44.86 Million | +17845.60% |
| 2017-12-31 | $250.00K | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more